quetiapine extended-release / Generic mfg. - LARVOL DELTA

Quetiapine Extended-Release and Peripheral Edema: A Case Report and Literature Review. (PubMed, Case Rep Psychiatry) - "While edema is more commonly associated with olanzapine and clozapine amongst second general antipsychotics, reports involving quetiapine-particularly the extended-release (XR) formulation-are rare. We describe the case of a 52-year-old woman with severe major depressive episode with psychotic features who was initiated on escitalopram and quetiapine immediate-release (IR) 100 mg/day, later switched to quetiapine XR 100 mg/day to improve adherence and reduce sedation...Literature review reveals few comparable reports, most involving higher doses or polypharmacy. This case highlights the importance of clinician awareness of quetiapine XR-associated edema, even at low doses, and supports dechallenge-rechallenge as a useful diagnostic approach to improve patient safety and adherence."

Journal • Anesthesia • Bipolar Disorder • Cardiovascular • CNS Disorders • Depression • Hematological Disorders • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia • Thrombosis

Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release. (PubMed, Eur Psychiatry) - No abstract available

HEOR • Journal • CNS Disorders • Depression • Psychiatry

Delirious mania with catatonic features as a presenting syndrome of anti-NMDAR encephalitis: a case report (ECNP 2025) - "Despite sequential trials of olanzapine (up to 20 mg/day), quetiapine XR (up to 300 mg/day), zuclopenthixol decanoate (150 mg intramuscular every months), paliperidone (6 mg/day), and adjunctive lithium carbonate (900 mg/day, there was no clinical improvement...Rituximab was started for long-term immunomodulation, maintaining remission over one year...ConclusionA comprehensive neurodiagnostic evaluation enables early diagnosis and treatment of anti-NMDAR encephalitis. Clinicians should consider autoimmune causes in atypical neuropsychiatric cases.[5]"

Case report • Clinical • Ataxia • Bipolar Disorder • CNS Disorders • Epilepsy • Mental Retardation • Mood Disorders • Movement Disorders • Psychiatry

Efficacy and safety of brexpiprazole in early-episode schizophrenia: post hoc analysis of clinical trials in adults and adolescents (ECNP 2025) - P3 | "For the trials in adults, patients aged 18–65 were randomised to placebo (total N=531), brexpiprazole (total N=1,093; 0.25, 1, 2 or 4 mg/day, or 2–4 mg/day, depending on the trial), or quetiapine extended-release (N=154; active reference in one trial). For the trial in adolescents, patients aged 13–17 were randomised to placebo (N=104), brexpiprazole 2–4 mg/day (N=110), or aripiprazole (N=102; active reference)... In this post hoc analysis of patients with early-episode schizophrenia, brexpiprazole was associated with greater improvement in schizophrenia symptoms than placebo. No new safety observations were made. Data previously presented at the 33rd European Congress of Psychiatry (EPA), 5–8 April 2025, Madrid, Spain."

Clinical • Retrospective data • CNS Disorders • Psychiatry • Schizophrenia

Developments in adjunctive treatment: Seltorexant versus quetiapine in managing major depressive disorder with insomnia symptoms (ECNP 2025) - P3 | "This presentation will focus on the results from a Phase 3, 26-week, international, double-blind, active-controlled study (NCT04513912) of adjunctive seltorexant 20 mg with quetiapine-extended release (XR) as a comparator in MDD with insomnia symptoms in a subgroup of participants (18-74 years) from the European Union and United Kingdom. Y. Flossbach is a full-time employee of Actelion Pharmaceuticals Ltd., a Johnson & Johnson company, and holds stock in Johnson & Johnson"

CNS Disorders • Depression • Insomnia • Major Depressive Disorder • Mood Disorders • Psychiatry • Sleep Disorder

Phenytoin-induced manic episode in a patient with epilepsy and cerebral palsy (ECNP 2025) - "His antiepileptic regimen included levetiracetam (1000 mg/day), oxcarbazepine (600 mg/day), and lacosamide (150 mg/day)...Phenytoin was tapered off with neurology consultation, and quetiapine XR (200 mg/day) was initiated...Future research should focus on elucidating the precise mechanisms underlying these paradoxical reactions and developing clinical guidelines for safer use in high-risk populations. In the interim, clinicians should weigh the potential risks against benefits when considering phenytoin for patients with complex neurological histories and consider alternative antiepileptic options when appropriate."

Clinical • Ataxia • Bipolar Disorder • Cerebral Palsy • CNS Disorders • Epilepsy • Mood Disorders • Movement Disorders • Psychiatry • Psychomotor Agitation

An MPAN case initially presenting with psychiatric manifestations (ECNP 2025) - "At the time of admission, her medications included buspirone (15 mg/day), valproic acid (1500 mg/day), and propranolol (40 mg/day)...Intramuscular biperiden was administered, followed by oral biperiden. Olanzapine was discontinued and quetiapine XR (450 mg/day) was prescribed instead...Informed consent was obtained. No conflicts of interest were declared."

Clinical • CNS Disorders • Depression • Dystonia • Mental Retardation • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • FTL

Patient characteristics associated with relative benefit of esketamine nasal spray versus quetiapine extended release on achieving remission in ESCAPE-TRD study (ECNP 2025) - P3 | "HRs of remission in ESK-NS versus QTP-XR by baseline characteristic subgroup Baseline characteristicHR (95% CI) ESK-NS versus QTP-XRRatio of HRs (95% CI)BMI Underweight/normal Overweight/obese Missinga 1.30 (0.91, 1.84) 1.90 (1.46, 2.48) 2.56 (1.41, 4.64) Overweight/obese versus underweight/normal weight: 1.47 (0.95, 2.27)Mean age at diagnosisb1.71 (1.40, 2.09)Per 5-year increase: 0.95 (0.88, 1.04)cNumber of previous treatment failures 2 ≥3 1.54 (1.21, 1.97) 2.03 (1.45, 2.84) ≥3 versus 2 previous treatment failures: 1.32 (0.87, 2.00)Number of MDD episodes 1 >1 1.65 (1.03, 2.64) 1.73 (1.39, 2.15) 1 versus >1 episode: 0.96 (0.57, 1.61)Mean duration of episoded1.75 (1.43, 2.14)Per 10-week increase: 1.00 (0.96, 1.03) Full analysis set. [a] ≥10% patients missing data, therefore missing data category included; [b] 34.2 years; [c] Ratio of HR <1.0 indicates relative benefit of ESK-NS decreases with age; [d] 66.7 weeks."

Clinical • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Assessment of patient-reported depression severity in subpopulation of ESCAPE-TRD study: esketamine nasal spray versus quetiapine extended release for treatment-resistant depression. (PubMed, Curr Med Res Opin) - P3 | "At 32 weeks, a significantly higher proportion of individuals in the esketamine NS group achieved remission and response compared to the quetiapine XR group (remission: 34.8% vs. 18.1%, RD [95% CI]: 16.7% [9.9%, 23.4%]; p < 0.001; response: 58.9% vs. 40.3%, RD [95% CI]:18.5% [10.9%, 26.2%]; p < 0.001). Using patient-reported PHQ-9 scoring to evaluate ESCAPE-TRD results, esketamine NS produced superior short- and long-term efficacy vs. quetiapine XR among individuals with TRD treated according to US label."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

C-SAPP: Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis (clinicaltrials.gov) - P4 | N=358 | Recruiting | Sponsor: VA Office of Research and Development | Trial completion date: Aug 2026 ➔ Aug 2027 | Trial primary completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

A Review of Pharmacokinetic and Pharmacodynamic Properties of Quetiapine IR and XR: Insights and Clinical Practice Implications. (PubMed, Cureus) - "Quetiapine XR leads to a slow drug release, delays time to maximum plasma concentration (Tmax) by two to four hours, reduces peak plasma concentration (Cmax) by 13%, and lowers fluctuations in plasma concentration. These differences may have implications for careful patient selection. Long-term studies are needed for the comparison of weight gain and metabolic adverse events."

Journal • PK/PD data • Review • Anesthesia • Bipolar Disorder • CNS Disorders • Depression • Infectious Disease • Mental Retardation • Psychiatry

Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression. (PubMed, J Comp Eff Res) - "Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK NS + OAD) versus quetiapine extended release plus an oral antidepressant (QTP XR + OAD) among adults with treatment-resistant depression (TRD). Under the scenario analysis, the cost-per-remitter for ESK NS + OAD compared with QTP XR + OAD was $15,133.66 lower in the commercial setting and $12,487.62 lower in the Medicaid setting. The findings suggest that ESK NS + OAD is a cost-effective treatment for adults with TRD compared with QTP XR + OAD in the commercial and Medicaid settings."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Adverse events associated with four atypical antipsychotics used as augmentation treatment for major depressive disorder: A pharmacovigilance study based on the FAERS database. (PubMed, J Affect Disord) - "It is suggesting a potential increased risk of various ADEs in patients with MDD when taking AAPs. The causal relationship and the exact mechanism between drugs and ADEs remains unclear, requiring further research."

Adverse events • Journal • Cardiovascular • CNS Disorders • Depression • Glaucoma • Inflammation • Major Depressive Disorder • Mental Retardation • Metabolic Disorders • Mood Disorders • Movement Disorders • Obsessive-Compulsive Disorder • Ophthalmology • Psychiatry • Restless Legs Syndrome • Sleep Disorder

SMART-BD: Sequential Multiple Assignment Randomized Trial for Bipolar Depression (clinicaltrials.gov) - P4 | N=2726 | Recruiting | Sponsor: Massachusetts General Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis. (PubMed, BMC Psychiatry) - "Holistically considering each endpoint and corresponding "time window", certain SGAs appeared to be efficient augmentation to anti-depressants for TRD, but aripiprazole was relatively more effective and better tolerated."

Clinical • Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study. (PubMed, Eur Neuropsychopharmacol) - P3 | "Patients receiving esketamine NS experienced greater improvements in functioning and productivity over 32 weeks versus quetiapine XR. These improvements demonstrate the clinical and functional benefit of treatment with esketamine NS for patients with TRD."

Journal • P3 data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Esketamine Nasal Spray vs Quetiapine Extended-Release: Examining Work Productivity Loss and Related Costs in Patients With Treatment-Resistant Depression. (PubMed, J Clin Psychiatry) - "By week 32, total WPL decreased from baseline by 45.3 pp and 32.5 pp in the esketamine and quetiapine cohorts (MD = 12.7 pp; 95% CI, 4.7-20.7 pp), with weekly cost savings of $543 and $390 (MD = $153; 95% CI, $57-$250), respectively. Among employed adults with TRD, esketamine treatment was associated with significantly larger improvements in WPL and related costs compared to quetiapine, suggesting greater benefits from patient well-being and employer perspectives."

Clinical • Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial. (PubMed, CNS Spectr) - No abstract available

Clinical • Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial. (PubMed, Br J Psychiatry) - "Esketamine nasal spray consistently demonstrated significant superiority over quetiapine extended release using all pre-specified definitions for remission and relapse. Sensitivity analyses supported the conclusions of the primary ESCAPE-TRD analysis and demonstrated robustness of the results."

Journal • P3 data • CNS Disorders • Depression • Psychiatry

Disease-specific quality of life with esketamine nasal spray versus quetiapine extended release in treatment resistant depression: Results from ESCAPE‑TRD (ECNP 2024) - P3 | "Conclusion :ESK-NS-treated patients experienced significantly greater improvements in HRQoL versus QTP‑XR; more patients reached clinically meaningful improvement and did so in a shorter time. Results suggest the superior clinical efficacy reported for ESK‑NS in ESCAPE-TRD was also perceived by patients, with favourable effects on HRQoL."

HEOR • CNS Disorders • Depression • Mood Disorders • Psychiatry

Treatment patterns of esketamine nasal spray amongst patients with treatment resistant depression in a phase IIIb study: Results from ESCAPE‑TRD (ECNP 2024) - P3 | "Introduction :ESCAPE-TRD (NCT04338321) was a randomised, phase IIIb trial comparing the efficacy and safety of esketamine nasal spray (ESK-NS) versus quetiapine extended release (Q-XR), when both were flexibly dosed alongside an ongoing selective serotonin/serotonin-norepinephrine reuptake inhibitor, in patients with treatment resistant depression (TRD). Of 336 patients randomised to ESK-NS, 334 received ≥1 dose of study treatment.Of 334 ESK-NS-treated patients, 21 (6.3%) and 313 (93.7%) received 28 or 56 mg as the starting dose, respectively. In patients who started at 56 mg, median time to escalation to 84 mg was 21 days (95% confidence interval: 15, 24).The most often administered dosages were 28, 56 and 84 mg for 6 (1.8%), 138 (41.3%) and 189 (56.6%) patients during treatment, respectively. One patient received doses of 56 mg and 84 mg on an equal number of days."

Clinical • P3 data • CNS Disorders • Depression • Mood Disorders • Psychiatry

Pharmacobezoar Associated Prolonged Clinical Course in a Patient with Immediate Release Quetiapine Overdose. (PubMed, J Med Toxicol) - "A massive quetiapine IR overdose with pharmacobezoars can cause a delayed increase in serum quetiapine concentrations."

Journal • CNS Disorders • Depression • Psychiatry

Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial. (PubMed, Psychiatry Investig) - "Lurasidone 160 mg/day was found to be non-inferior to QXR 600 mg/day in the treatment of schizophrenia with comparable efficacy and tolerability. Adverse effects of lurasidone were generally tolerable, and beneficial effects on metabolic parameters can be expected."

Clinical • Journal • CNS Disorders • Dyslipidemia • Psychiatry • Schizophrenia

Case Management Approaches in Patients with Bipolar Disorders and Alcohol Use Disorders (ISBD 2024) - "All patients were initiated on treatment with naltrexone 50 mg/zi, added to their ongoing mood-stabilizer treatment (valproate or carbamazepine +/- quetiapine XR). Adding naltrexone for AUD in patients with type I BD is a useful case management approach in patients with this dual diagnosis."

Clinical • Addiction (Opioid and Alcohol) • Bipolar Disorder • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Personality Disorder • Psychiatry

Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression. (PubMed, Eur Neuropsychopharmacol) - P3 | "Data were consistent with established safety profiles, with no new safety signals identified. Alongside greater efficacy, the demonstrably more favourable tolerability profile of esketamine NS versus quetiapine XR further supports its use for TRD."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry